GPCR — Structure Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.36bn
- $477.80m
- 44
- 34
- 13
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.57 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.24% | ||
| Return on Equity | -18.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 28th, 2019
- Public Since
- February 3rd, 2023
- No. of Employees
- 163
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 172,028,543
- Address
- 611 Gateway Blvd Suite 223, SOUTH SAN FRANCISCO, 94080
- Web
- https://structuretx.com/
- Phone
- Auditors
- Ernst & Young LLP
Upcoming Events for GPCR
Structure Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Structure Therapeutics Inc Earnings Release
Similar to GPCR
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Structure Therapeutics share price?
As of Today at 23:28 UTC, shares in Structure Therapeutics are trading at $23.74. This share price information is delayed by 15 minutes.
How has the Structure Therapeutics share price performed this year?
Shares in Structure Therapeutics last closed at $23.74 and the price had moved by -39.1% over the past 365 days. In terms of relative price strength the Structure Therapeutics share price has underperformed the S&P500 Index by -43.78% over the past year.
What are the analyst and broker recommendations for Structure Therapeutics?
The overall consensus recommendation for Structure Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Structure Therapeutics dividend yield?
Structure Therapeutics does not currently pay a dividend.
Does Structure Therapeutics pay a dividend?
Structure Therapeutics does not currently pay a dividend.
When does Structure Therapeutics next pay dividends?
Structure Therapeutics does not currently pay a dividend.
How do I buy Structure Therapeutics shares?
To buy shares in Structure Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Structure Therapeutics?
As of the previous close price of $23.74, shares in Structure Therapeutics had a market capitalisation of $1.36bn.
Where are Structure Therapeutics shares listed?
Here are the trading details for Structure Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GPCR
What kind of share is Structure Therapeutics?
Based on an overall assessment of its quality, value and momentum Structure Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Structure Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Structure Therapeutics is $80.15. That is 237.62% above the last closing price of $23.74.
Analysts covering Structure Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.07 for the next financial year.
Find out moreWhat is the trend in the Structure Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Structure Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -33.44%.
As of the last closing price of $23.74, shares in Structure Therapeutics were trading -24.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Structure Therapeutics PE Ratio?
The Structure Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $23.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Structure Therapeutics?
We do not have data on Structure Therapeutics' directors